Wills Hughes-Wilson

Corporate Officer/Principal at MEREO BIOPHARMA GROUP PLC

Net worth: 860 $ as of 29/04/2024

53 year

Health Technology

Consumer Services

Wills Hughes-Wilson active positions

Companies	Position	Start	End
MEREO BIOPHARMA GROUP PLC	Corporate Officer/Principal	28/02/2018	-

Companies	Position	Start	End
SWEDISH ORPHAN BIOVITRUM AB	Public Communications Contact	03/07/2012	31/12/2017
	General Counsel	31/01/2012	03/07/2012
	Corporate Officer/Principal	31/01/2012	31/12/2017
Genzyme Therapeutics Ltd. Genzyme Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Genzyme Therapeutics Ltd. develops transformative therapies for patients affected by rare and debilitating diseases. Its treatment areas include thyroid cancer, sclerosis, Fabry disease and Pompe. The company was founded on November 5, 2001 and is headquartered in Oxford, the United Kingdom.	Corporate Officer/Principal	-	-
European Biopharmaceutical Enterprises European Biopharmaceutical Enterprises BiotechnologyHealth Technology European Biopharmaceutical Enterprises develops biological products. The private company is based in Brussels, Belgium.	Director/Board Member	-	-
Genzyme Corp. Genzyme Corp. Medical SpecialtiesHealth Technology Genzyme Corp. engages in development and manufacture of specialty therapeutic, surgical and diagnostic product. It serves in the areas of rare genetic diseases, multiple sclerosis, cardiovascular diseases and endocrinology. The company was founded on June 8, 1981 and is headquartered in Cambridge, MA.	Corporate Officer/Principal	-	-

University of Durham

Graduate Degree

International

Operational

Corporate Officer/Principal	4
Public Communications Contact	1
General Counsel	1

Sectoral

Health Technology	6
Consumer Services	2

Positions held

Active

Inactive

Listed companies

Private companies

Listed companies	2
SWEDISH ORPHAN BIOVITRUM AB	Health Technology
MEREO BIOPHARMA GROUP PLC	Health Technology

Private companies	3
Genzyme Corp. Genzyme Corp. Medical SpecialtiesHealth Technology Genzyme Corp. engages in development and manufacture of specialty therapeutic, surgical and diagnostic product. It serves in the areas of rare genetic diseases, multiple sclerosis, cardiovascular diseases and endocrinology. The company was founded on June 8, 1981 and is headquartered in Cambridge, MA.	Health Technology
European Biopharmaceutical Enterprises European Biopharmaceutical Enterprises BiotechnologyHealth Technology European Biopharmaceutical Enterprises develops biological products. The private company is based in Brussels, Belgium.	Health Technology
Genzyme Therapeutics Ltd. Genzyme Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Genzyme Therapeutics Ltd. develops transformative therapies for patients affected by rare and debilitating diseases. Its treatment areas include thyroid cancer, sclerosis, Fabry disease and Pompe. The company was founded on November 5, 2001 and is headquartered in Oxford, the United Kingdom.	Health Technology